Literature DB >> 15538985

The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.

Grace A Lee, Madhu N Rao, Carl Grunfeld.   

Abstract

Since the introduction of HIV protease inhibitors (PIs), disorders of glucose and lipid metabolism have emerged. In dissecting out the direct effect on lipid and glucose metabolism, it has become apparent that individual PIs have different effects on metabolism. Some PIs such as indinavir acutely induce insulin resistance. PIs have also been shown to cause other disorders of glucose metabolism, including impairment of insulin secretion and increased endogenous glucose production. Individual PIs also have different effects on lipid metabolism. Ritonavir predominantly increases triglyceride and very low-density lipoprotein cholesterol levels. Limited studies in HIV-negative volunteers suggest that several of the PIs do not increase low-density lipoprotein cholesterol levels. This review examines the direct effects of PIs on glucose and lipid metabolism by assessing prospective studies of HIV-infected and healthy normal volunteers, and in vitro studies.

Entities:  

Year:  2004        PMID: 15538985     DOI: 10.1007/s11908-004-0067-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  74 in total

1.  Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.

Authors:  Esteban Martínez; Pere Domingo; María J Galindo; Ana Milinkovic; Juan A Arroyo; Francisco Baldovi; María Larrousse; Agathe León; Elisa de Lazzari; José M Gatell
Journal:  Clin Infect Dis       Date:  2004-03-15       Impact factor: 9.079

2.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Authors:  K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

3.  Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices.

Authors:  Qiang Tong; Jean-Louis Sankalé; Colleen M Hadigan; Guo Tan; Eric S Rosenberg; Phyllis J Kanki; Steven K Grinspoon; Gökhan S Hotamisligil
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

4.  Indinavir induces acute and reversible peripheral insulin resistance in rats.

Authors:  Paul W Hruz; Haruhiko Murata; Haijun Qiu; Mike Mueckler
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

Review 5.  Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Authors:  Morris Schambelan; Constance A Benson; Andrew Carr; Judith S Currier; Michael P Dubé; John G Gerber; Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Kathleen Mulligan; William G Powderly; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2002-11-01       Impact factor: 3.731

6.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

7.  Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

Authors:  Robert L Murphy; Ian Sanne; Pedro Cahn; Praphan Phanuphak; Lisa Percival; Thomas Kelleher; Michael Giordano
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

8.  Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.

Authors:  Michael P Dubé; Dajun Qian; Hannah Edmondson-Melançon; Fred R Sattler; Diane Goodwin; Carmen Martinez; Vanessa Williams; Debra Johnson; Thomas A Buchanan
Journal:  Clin Infect Dis       Date:  2002-07-23       Impact factor: 9.079

9.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

10.  A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.

Authors:  Cesar Fisac; Nuria Virgili; Elena Ferrer; Maria J Barbera; Emilio Fumero; Concepcio Vilarasau; Daniel Podzamczer
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

View more
  9 in total

Review 1.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

2.  Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia.

Authors:  Bo Jiang; Alok R Khandelwal; Lynette K Rogers; Valeria Y Hebert; James J Kleinedler; James H Zavecz; Weibin Shi; A Wayne Orr; Tammy R Dugas
Journal:  Toxicol Sci       Date:  2010-07-09       Impact factor: 4.849

3.  Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptors.

Authors:  Partab Rai; Tejinder Singh; Rivka Lederman; Amrita Chawla; Dileep Kumar; Kang Cheng; Gautam Valecha; Peter W Mathieson; Moin A Saleem; Ashwani Malhotra; Pravin C Singhal
Journal:  Cell Signal       Date:  2014-12-24       Impact factor: 4.315

Review 4.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

5.  Hyperglycemia exacerbates antiretroviral drug combination induced blood-brain barrier endothelial toxicity.

Authors:  Shikha Prasad; Ravi K Sajja; Mohammad A Kaisar; Luca Cucullo
Journal:  Neurotoxicology       Date:  2016-06-23       Impact factor: 4.294

6.  Understanding diabetes in patients with HIV/AIDS.

Authors:  Sanjay Kalra; Bharti Kalra; Navneet Agrawal; Ag Unnikrishnan
Journal:  Diabetol Metab Syndr       Date:  2011-01-14       Impact factor: 3.320

7.  South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

Authors:  Sanjay Kalra; Ambika Gopalakrishnan Unnikrishnan; Syed Abbas Raza; Ganpathy Bantwal; Manash P Baruah; Tint Swe Latt; Dina Shrestha; Mathew John; Prasad Katulanda; Noel Somasundaram; Rakesh Sahay; Faruque Pathan
Journal:  Indian J Endocrinol Metab       Date:  2011-10

8.  Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction.

Authors:  Gerard Wong; Janine M Trevillyan; Benoit Fatou; Michelle Cinel; Jacquelyn M Weir; Jennifer F Hoy; Peter J Meikle
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

9.  Association of HIV-1 Infection and Antiretroviral Therapy With Type 2 Diabetes in the Hispanic Population of the Rio Grande Valley, Texas, USA.

Authors:  Juan Carlos Lopez-Alvarenga; Dora A Martinez; Alvaro Diaz-Badillo; Liza D Morales; Rector Arya; Christopher P Jenkinson; Joanne E Curran; Donna M Lehman; John Blangero; Ravindranath Duggirala; Srinivas Mummidi; Ruben D Martinez
Journal:  Front Med (Lausanne)       Date:  2021-07-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.